Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S0140-6736(21)02391-6 http://scihub22266oqcxt.onion/10.1016/S0140-6736(21)02391-6 35367005!8970581!35367005     free     free     free       Lancet 2022 ; 399 (10332): 1347-1358 Nephropedia Template TP {{tp|p=35367005|t=2022. Acute coronary syndromes |pdf=|usr=}}{{35367005}} gab.com Text Acute coronary syndromes JO: Lancet http://www.kidney.de/pget.php?&tw=1&pmid=35367005 #FOAvip Although substantial progress has been made in the diagnosis and treatment of acute coronary syndromes, cardiovascular disease remains the leading cause of death globally, with nearly half of these deaths due to ischaemic heart disease. The broadening availability of high-sensitivity troponin assays has allowed for rapid rule-out algorithms in patients with suspected non-ST-segment elevated myocardial infarction (NSTEMI). Dual antiplatelet therapy is recommended for 12 months following an acute coronary syndrome in most patients, and additional secondary prevention measures including intensive lipid-lowering therapy (LDL-C <1.4 mmol/L), neurohormonal agents, and lifestyle modification, are crucial. The scientific evidence for diagnosis and management of acute coronary syndromes continues to evolve rapidly, including adapting to the COVID-19 pandemic, which has impacted all aspects of care. This Seminar provides a clinically relevant overview of the pathobiology, diagnosis, and management of acute coronary syndromes, and describes key scientific advances. Twit Text FOAVip Acute coronary syndromes ????Lancet http://www.kidney.de/pget.php?&tw=1&pmid=35367005 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35367005 #FOAvip English Wikipedia <ref>{{Cite pmid|35367005}}</ref> Acute coronary syndromes #MMPMID35367005 Bergmark BA; Mathenge N; Merlini PA; Lawrence-Wright MB; Giugliano RP Lancet 2022[Apr]; 399 (10332): 1347-1358 PMID35367005show ga Although substantial progress has been made in the diagnosis and treatment of acute coronary syndromes, cardiovascular disease remains the leading cause of death globally, with nearly half of these deaths due to ischaemic heart disease. The broadening availability of high-sensitivity troponin assays has allowed for rapid rule-out algorithms in patients with suspected non-ST-segment elevated myocardial infarction (NSTEMI). Dual antiplatelet therapy is recommended for 12 months following an acute coronary syndrome in most patients, and additional secondary prevention measures including intensive lipid-lowering therapy (LDL-C <1.4 mmol/L), neurohormonal agents, and lifestyle modification, are crucial. The scientific evidence for diagnosis and management of acute coronary syndromes continues to evolve rapidly, including adapting to the COVID-19 pandemic, which has impacted all aspects of care. This Seminar provides a clinically relevant overview of the pathobiology, diagnosis, and management of acute coronary syndromes, and describes key scientific advances. |*Acute Coronary Syndrome/diagnosis/therapy[MESH] |*COVID-19[MESH] |Humans[MESH] |Pandemics[MESH] |Secondary Prevention[MESH]Acute coronary syndromes (epmc).pdf DeepDyve Pubget Overpricing